Bounsavath Nola, MD
Internal Medicine · Wichita, KSNPI 1356336515
Payments from drug & device makers
Across 147 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$609
- Amgen$419
- Sanofi-aventis U.S. LLC$303
- Novo Nordisk$240
- Lilly USA, LLC$168
- Amarin Pharma, Inc.$162
- plus $560 from 12 others
What the payments were for
- Food & beverage$2,459100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 28 | $609 |
| Amgen(2 entities) | 25 | $419 |
| Sanofi-aventis U.S. LLC | 19 | $303 |
| Novo Nordisk | 15 | $240 |
| Lilly USA, LLC | 12 | $168 |
| Amarin Pharma, Inc. | 10 | $162 |
| Pfizer | 9 | $133 |
| Novartis | 5 | $73 |
| Astellas Pharma US Inc | 5 | $72 |
| Merck | 5 | $66 |
| Bayer | 3 | $56 |
| Johnson & Johnson | 3 | $52 |
| Mylan Specialty L.p. | 2 | $25 |
| AbbVie(2 entities) | 2 | $23 |
| Eisai Inc. | 1 | $17 |
| Abbott | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,459 in reported general payments places this provider in the 85th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 139 | $116,438 |
| MounjaroTirzepatide | 79 | $85,738 |
| FarxigaDapagliflozin Propanediol | 44 | $51,391 |
| JanuviaSitagliptin Phosphate | 29 | $42,446 |
| OzempicSemaglutide | 20 | $38,863 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 31 | $35,198 |
| JardianceEmpagliflozin | 22 | $28,936 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $22,850 |
| JanumetSitagliptin Phos/Metformin Hcl | 27 | $22,429 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 71 | $21,883 |
| RybelsusSemaglutide | 13 | $19,585 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $17,750 |
| MyrbetriqMirabegron | 15 | $16,492 |
| XareltoRivaroxaban | 14 | $16,305 |
| VraylarCariprazine Hcl | 11 | $16,000 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $133 | $116,438139 claims |
| Lilly USA, LLCMounjaro | $168 | $85,73879 claims |
| MerckJanuvia, Janumet, Janumet Xr | $66 | $82,62568 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $609 | $74,24080 claims |
| Novo NordiskOzempic, Rybelsus | $240 | $58,44833 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $303 | $35,19831 claims |
| AbbVieVraylar, Linzess, Synthroid | $23 | $27,63155 claims |
| Astellas Pharma US IncMyrbetriq | $72 | $16,49215 claims |
| Johnson & JohnsonXarelto | $52 | $16,30514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Wichita
- Donna SweetWichita$348K
- Wissam SalibaWichita$157K
- Atieh JibbeWichita$121K
- Brent DuranWichita$91K
- Thanh TruongWichita$28K
- Maya EstephanWichita$12K
- Baoluan NguyenWichita$7K
- Jane GitauWichita$5K
- Martin KankamLeavenworth$63.4M
- Mark HamblinKansas City$5.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.